BluntForceOptions

"The stock market is never obvious. It is designed to fool most of the people, most of the time."—Jesse Livermore. After almost four decades in this game, it’s a reminder I come back to often, and one every serious market professional eventually learns. This business rewards process, discipline, and execution—not hype or guesswork. The market’s job is to challenge your conviction; your job is to stay grounded in the work. With that said, I invest heavily in institutional-grade research platforms and technical tools to ensure every thesis is backed by high-signal data. My approach is a synthesis of advanced technical analysis and deep forensic due diligence. I leverage this framework to challenge consensus and discover the disconnect between market sentiment and data-driven reality. Hope is not a strategy. I trade on a repeatable process designed to put the mathematical odds in my favor. Tune out the noise. Stick to the plan. Focus on execution. Wishing everyone continued success and good trading ahead.

$TNXP New long position in Tonix Pharma today. This is another one caught in the same biotech flush that's taken out nearly everything in the space this past month. The stock is down about 45% over that stretch and is sitting a few cents above its 52-wk low. This isn't a pre-revenue science project, though. Tonix has three FDA-approved products on the market. The lead is TONMYA, the first new fibromyalgia drug in over 15 yrs, which launched last Nov and nearly tripled net sales Q over Q in Q2. Behind the commercial biz sits a deeper pipeline than the valuation implies. TNX-102 SL, the same molecule as TONMYA, is in Phase 2 for both major depressive disorder and acute stress disorder, with ASD topline data guided for 1Q'27. Beyond that: TNX-1300 in mid-Phase 2 for cocaine intoxication, TNX-4800 for Lyme disease prevention heading into a Phase 2 field study, TNX-1500 for transplant rejection, and TNX-2900 for Prader-Willi, which carries FDA Orphan Drug and Rare Pediatric Disease designations. The bal sheet is what initially caught my eye. Tonix had $176.2M in cash at 6/30 and no debt, against a MC of roughly $92M. Haircut that for a full quarter of burn and the stock is still trading well below cash. The market is pricing the commercial biz and the PL at less than zero. Technicals on my screen... • RSI(14) at 18.9, pinned in oversold territory for most of Oct • Slow stochs hooking up off the floor, %K crossing over %D • ADX north of 60 shows how one-sided the selling has been, but readings that stretched tend to show up late in a move, not early • Volume has dried up the last several sessions as price tightens just above the low Levels I'm watching... • $5.01: 52-wk low • $6.55: 20-day SMA, first real test on any bounce • $9.83: 50-day SMA • $10.77 / $12.58: 100-day and 200-day SMAs Q3 numbers hit Nov 9 before the open. TONMYA script trends and an updated cash figure are what matter to me. All told, I took a 1/3 position in the low $5s this morning. The sizing is deliberate. This is a commercial launch that is still burning cash, and the Street likely wants to see the runway extended before it pays up, so I'm leaving room to add. At a neg EV with approved products already generating revs, I really like the risk/reward from here. As always, I'm just sharing my work here. DYOR and check everything. NFA.

$ACH Been aggressively buying the stock down in that $0.20 pocket. Daily chart is putting in a clean bottoming structure and starting to turn nicely... exactly what I want to see off recent capitulation.

$FNUC Solid action right out of the gate this morning. Getting the exact structural bounce we mapped out on the daily chart. The setup is tracking perfectly off the recent lows. Looking for volume to confirm and drive continuation back above the $1.00 threshold and towards the SMA 50. Giddy up!

$EYPT Kevin Tang just filed a 13G showing 9.6% of EyePoint. I doubled my position today at $0.37. The filing... • 8,250,200 shares, 9.6%. Initial filing, not an amendment • Event date 10/20/2026, one session after the LUCIA crash. Filed 10/27, on the deadline • Crossing 5% after the crash means at least ~3.9M shares were bought post-readout at sub-$0.50 prices. His Q3 13F, due by Nov 16, shows what he held as of Sept 30 • Passive filing. Not an activist campaign unless a 13D follows Why it matters: Tang is known for buying broken biotechs below cash. His Concentra vehicle has done it repeatedly. When he takes nearly 10% of a stock trading at 27 cents on the dollar, it tells you where he thinks the floor is. The math at $0.36: ~$1.33 cash per share, so the stock trades at 27 cents on the dollar. Tang's stake is worth about $3M on the tape and represents about $11M of company cash. That gap is the trade. Next: Q3 print Nov 4 (est), Tang's 13F by Nov 16, and any 13D. Cash still burns until the cuts take hold, so I'm scaling in. Avg is now around $0.39. I like having Tang on my side of the trade. Again, just sharing my work here. Check everything yourself. NOT financial advice. Partial filing below (first 2 pages only)

$VYGR CTAD 2026 Alzheimer’s pipeline update. ICYMI: Voyager just dropped their PR detailing two upcoming poster presentations at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference... and the market, IMO, is still sleeping on this setup down in the $1.70s after throwing VYGR out with the bathwater during the recent sector-wide biotech capitulation. The clinical anchors being featured: • "First-in-human study design of VY1706, a systemically administered blood-brain barrier (BBB)-penetrant tau lowering gene therapy in early Alzheimer's disease (# P055)" • "Baseline characteristics of participants enrolled in a multiple ascending dose study of the C-terminal targeting anti-tau antibody VY7523 in early Alzheimer's disease (# P054)" I'm long the common equity and have been actively writing puts to farm premium while the thesis plays out. Between the systemic BBB-penetrant capabilities, these progression updates, and the ongoing optionality of their TRACER AAV capsid discovery platform, the asymmetric risk/reward here, IMO, remains fully intact.

$FNUC The setup here is clean. We spent weeks in extreme oversold territory, but with oscillators officially hooking up off the lows, we're finally getting that technical pivot we were looking for. I'm tracking a mechanical relief rally to close the massive gap between the current price and the 50 SMA. The reversion trade is on watch.

$MOS catching a solid bid today off the recent flush bottom. Pushing into the mid-$18s with solid price action and buyers stepping in.

$WHR Everyone wants to "buy low and sell high" until "low" actually shows up on the screen looking terrifying. Earnings were ugly... no surprise there. The guide-down is out, the tape is flushed, and retail is convinced this 115-yr-old American cornerstone will never sell another appliance. Peak pessimism is precisely where asymmetric risk/reward begins. Trying to time the exact tick is a fool’s errand. If your horizon is measured in quarters instead of intraday noise, this is the zone where true cost bases are built. You don’t need the absolute bottom to capture generational returns... just the discipline to scale in while everyone else runs for the exit. Stepping in right here and starting to build. Giddy up.

$SLDB Solid Bio continues demonstrating the depth of its clinical PL, announcing European Commission Orphan designation for SGT-212 in Friedreich’s Ataxia. Beyond the regulatory incentives, execution in the Phase 1b FALCON trial is tracking well: 5 patients dosed utilizing their novel dual-route administration (stereotactic MRI-guided brain delivery + systemic IV), clean tolerability with zero treatment-related SAEs, and initial clinical data slated for Q1 2027. Solid clinical progress for the FA program as their lead DMD candidate (SGT-003) continues forward.

$SPCX Bernstein out raising their SpaceX target to $267 from $248. Douglas Harned flags that while orbital data centers are the ticket to a multi-trillion-dollar valuation, aggressive terrestrial AI builds and robust Enterprise/Gov connectivity are significantly lifting the baseline revenue path right now. Sideline bears were screaming for sub-$100 fills, while Wall Street keeps pushing their price targets higher.

For those mapping out positioning for the next two weeks, here's the AI & Big Tech earnings gauntlet: Week 1 (Oct 26): • Mon: CDNS, RMBS, AMKR • Tue: STX, NXPI, BA, HOOD • Wed: MSFT, GOOGL (Hyperscaler Capex), KLAC, VRT • Thu: AMZN (AWS), INTC, SNDK, LLY • Fri: XOM, CVX Week 2 (Nov 02): • Mon: PLTR, ON • Tue: AMD (GPU Catalyst), ANET, SHOP • Wed: ARM, QCOM, DDOG • Thu: NET, LITE With memory and neoclouds under pressure, hyperscaler forward guidance and infrastructure spend will dictate the broader tape. Trade 'em well... and stay safe out there. Data source: @finviz_com $MSFT $GOOGL $AMZN $INTC $AMD $PLTR

For those planning out the week ahead, here's your macro roadmap: Tuesday kicks off active data flow with Durable Goods (8:30 AM ET), Case-Shiller home prices (9:00 AM ET), consumer confidence, and new home sales (10:00 AM ET). Wednesday afternoon brings the marquee event of the week: the Fed Interest Rate Decision at 2:00 PM ET, followed by the press conference at 2:30 PM ET where markets will parse every word on the future rate path. There is zero breather Thursday morning at 8:30 AM ET, with the Advance Q3 GDP print landing right alongside the Core PCE inflation index, consumer spending, and weekly Jobless Claims. Friday wraps up with the Employment Cost Index (8:30 AM ET) and Chicago PMI (9:45 AM ET). Stay nimble through Wednesday's policy statement and Thursday's growth barrage. Protect your capital, and happy trading! Data courtesy of @finviz_com $SPY $QQQ $DIA $TLT $VIX

$FNUC We tore the fundamental wrapper apart when this was trading at $1.80 ish. It's since been obliterated down to $0.64. I just stepped in with a 10,000-share starter position today. To be clear... my thesis on the corporate opacity hasn't changed. This is purely a mechanical mean-reversion trade. The broad micro-cap flush has completely pegged the indicators here. The daily RSI (14) is sitting at a mathematically washed-out 14.64, and Slow Stochs are buried at 2.84. We're in extreme structural oversold territory. And if you look at the historical price action, any major leg down has resulted in a swift relief rally to test the descending 50-day SMA. That 50 SMA is currently parked at $1.36. I'm playing strictly for that reversion, which represents a 110%+ move from current levels. The fundamentals are still a black box, but the asymmetric math on this setup is too heavy to ignore, IMO. Then there’s the catalyst. The Engo Valley maiden resource was guided to mid-Q3 2026 and still hasn’t landed, so it’s live at any point. At $0.654, the entire co is a ~$23.6M MC with Pine Ridge 100% owned, Tallahassee’s 52.2 Mlbs, the Ubaryon stake alongside Urenco, and Kadmos all in there. A positive print into a float this flushed out has nothing left to sell into it. That’s gap risk pointed up, and it is not priced here. Just my two cents and NFA. Giddy up!

$MGNX Stepped in and bought a half position at $2.31. Here’s why: MacroGenics delivered at ESMO this morning. Interim Phase 1 data for MGC026, its B7-H3 antibody-drug conjugate, showed durable responses across multiple tumor types and a clean safety profile. Based on these results, the co plans to open a front-line head and neck cohort combining MGC026 with Keytruda in early 2027. This is a positive readout, and management executed exactly what it laid out back in July. The stock is down ~36% anyway. Here's what was actually reported. • SCCHN cohort (heavily pretreated, median 3 prior lines): 27% best overall response, 6 of 22. That's 4 confirmed PRs and 2 unconfirmed. Disease control 64%. • Dose escalation, at least 6 mg/kg across 10 tumor types: 29% confirmed ORR, median duration of response 10.2 months. • Zero ILD, pneumonitis or ocular toxicity across all 85 patients treated. For an exatecan-payload ADC, that's the headline that matters. • No treatment-related discontinuations in SCCHN. Grade 3+ events were mostly anemia and neutropenia, described as manageable and reversible. • Stage 2 of the SCCHN cohort is enrolling, with updated data expected mid-2027. The bal sheet is where it gets interesting, IMO... • Pro forma cash of $327M as of June 30, after the Bora manufacturing sale and the Sanofi and Gilead milestones. • 63.65M shares outstanding. That's $5.14 per share in pro forma cash. • At ~$2.34, the market cap is ~$149M. You're paying roughly 45 cents on the dollar for the cash alone. • Runway guided through 2028, so no near-term raise is needed to reach the next readout. The way I see it, the tape sold the 2 unconfirmed PRs and the heme tox line, ignored the safety profile that differentiates this ADC, and ignored a cash pile worth more than double the market cap. That's the kind of disconnect I want to step into. Regarding the tape... a gap through the 20, 50, 100 and 200-day on 8x avg volume, with daily RSI at 26. That's capitulation-grade selling into a positive data release. Levels I'm watching: today's low in the $2.25 area, then the $2.00 to $2.20 base the stock built before the March breakout. The 200-day sits overhead near $3.40, and yesterday's close of $3.63 is the gap fill. Bottom line: the event risk is behind it, the cash isn't going anywhere, and the market is pricing the pipeline near zero. That's where asymmetric setups come from. Just sharing my work. Please check everything yourself. NOT financial advice.

$AIXI ripping hard in the premarket 🚀